Precision Biosciences
Gene editing for genetic cure
Durham, NC, US
Precision Biosciences is a biotechnology company focused on developing gene editing therapies for cancer immunotherapy.
Problem Statement
The company aims to address unmet medical needs in cancer through the development of gene-edited immunotherapies.
Core Technology
gene editing for cancer immunotherapy
Key Differentiators
novel and proprietary ARCUS® genome editing platform
Clinical Focus
Oncology
Company Info
- Business Model
- Licensing
- Total Funding
- 103,500,000
- Website
- www.precisionbiosciences.com
Clinical & IP
Clinical Validation
Phase 1 ELIMINATE-B (HBV): Up to 69% HBsAg reduction, well-tolerated, durable effects. PBGENE-DMD: Preclinical proof showing 50-65% CK reduction, 81-84% sustained muscle force recovery. Both received FDA Fast Track. PBGENE-DMD has FDA Orphan Drug Designation. IND cleared; FUNCTION-DMD Phase 1/2 launching Q1-Q2 2026.
MedStartr Index Score
?What do you think of Precision Biosciences?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.